Angiotensin-converting enzyme (ACE) gene II genotype protects against the development of diabetic peripheral neuropathy in type 2 diabetes mellitus

Journal of Diabetes

Volumn 4, Issue 3, 2012, Pages 257-261

  Mansoor, Qaisar ^a   Javaid, Amara ^a   Bilal, Nighat ^a   Ismail, Muhammad ^a  

^a PAKISTAN INSTITUTE OF MEDICAL SCIENCES   (Pakistan)

Author keywords

Angiotensin converting enzyme (ACE) I D polymorphism; Diabetic peripheral neuropathy; Type 2 diabetes mellitus

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2;

ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIABETIC PATIENT; FEMALE; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL;

ALLELES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DNA MUTATIONAL ANALYSIS; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INDEL MUTATION; LINKAGE DISEQUILIBRIUM; PEPTIDYL-DIPEPTIDASE A; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 84865324377     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/j.1753-0407.2012.00205.x     Document Type: Article

References (31)

1. Wada R, Yagihashi S. Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann N Y Acad Sci. 2005; 1043: 598-604.
2. 1-receptor in atherosclerosis. J Hum Hypertens. 2002; 16: 26-33.
3. Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab. 2005; 16: 120-6.
4. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity. Circ Res. 2002; 91: 406-13.
5. Mollnau H, Wendt M, Szocs K et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res. 2002; 90: 58-65.
6. Wang HD, Xu S, Johns DG et al. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res. 2001; 88: 947-53.
7. Escobales N, Crespo MJ. Oxidative-nitrosative stress in hypertension. Curr Vasc Pharmacol. 2005; 3: 231-46.
8. Cotter MA, Cameron NE. Effect of the NAD(P)H oxidase inhibitor, apocynin, on peripheral nerve perfusion and function in diabetic rats. Life Sci. 2003; 73: 1813-24.
9. Haas LB. Chronic complications of diabetes mellitus. Nurs Clin North Am. 1993; 28: 71-85.
10. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA. 2002; 288: 2579-88.
11. Ito H, Tsukui S, Kanda T, Utsugi T, Ohno T, Kurabayashi M. Angiotensin-converting enzyme insertion/deletion polymorphism and polyneuropathy in type 2 diabetes without macroalbuminuria. J Int Med Res. 2002; 30: 476-82.
12. Stephens JW, Dhamrait SS, Acharya J, Humphries SE, Hurel SJ. A common variant in the ACE gene is associated with peripheral neuropathy in women with type 2 diabetes mellitus. J Diabetes Complications. 2006; 20: 317-21.
13. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/Deletion polymorphism in the angiotensin I-Converting enzyme gene accounting for half the variance of serum enzyme level. J Clin Invest. 1990; 86: 1343-6.
14. Cambien F. The aniotensin-converting enzyme (ACE) genetic polymorphism: Its relation with plasma ACE level and myocardial infarction. Clin Genet. 1994; 46: 94-101.
15. Pasha MA, Khan AP, Kumar R et al. Variations in angiotensin-converting enzyme gene insertion/deletion polymorphism in Indian populations of different ethnic origins. J Biosci. 2002; 27: 67-70.
16. Ay C, Bencur P, Vormittag R et al. The angiotensin-converting enzyme insertion/deletion polymorphism and serum levels of angiotensin-converting enzyme in venous thromboembolism. Data from a case control study. Thromb Haemost. 2007; 98: 777-82.
17. Sambrook J, Fritich EF, Maniatis T. Molecular cloning: A Laboratory Manual, 2nd edn. Cold Spring Harbor Laboratory Press, New York, 1989.
18. Batzer MA, Arcot SS, Phinney JW et al. Genetic variation of recent Alu insertions in human populations. J Mol Evol. 1996; 42: 22-9.
19. Javaid A, Mansoor Q, Bilal N, Bilal A, Shaukat U, Ismail M. ACE Gene DD Genotype Association with Obesity in Pakistani Population. Intl J Bioautomation. 2011; 15: 49-56.
20. Grzeszczak W, Zychma MJ, Lacka B, Zukowska-Szczechowska E. Angiotensin I converting enzyme gene polymorphisms: Relationship nephropathy in patients with non insulin dependent diabetes mellitus. J Am Soc Nephrol. 1998; 9: 1664-9.
21. Jeffers BW, Estacio RO, Raynolds MV, Schrier RW. Angiotensin converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus and its relationship with diabetic nephropathy. Kidney Int. 1997; 52: 473-7.
22. Naresh VVS, Reddy ALK, Sivaramakrishna G, Sharm PVGK, Vardhan RV, Siva Kumar VS. Angiotensin converting enzyme gene polymorphism in type II diabetics with nephropathy. Indian J Nephrol. 2009; 19: 145-8.
23. Hsieh MC, Lin SR, Hsieh TJ et al. Increased frequency of angiotensin-converting enzyme DD genotype in patients with type 2 diabetes in Taiwan. Nephrol Dial Transplant. 2000; 15: 1008-13.
24. Mansoor Q, Bilal N, Qureshi S, Qureshi O, Javaid A, Ismai M. Gender Based Disparities in ACE I/D Polymorphism Associated with Progression of Diabetic Nephropathy in Pakistani Patients with Type 2 Diabetes Mellitus. Int J Diabetes Metab. 2010; 18: 67-71.
25. Degirmenci I, Kebapci N, Basaran A et al. Frequency of angiotensin-converting enzyme gene polymorphism in Turkish type 2 diabetic patients. Int J Clin Pract. 2005; 59: 1137-42.
26. Ruddy MC. Angiotensin II receptor blockade in diabetic nephropathy. Am J Hypertens. 2002; 15: 468-71.
27. Lewis EJ. The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. Am J Hypertens. 2002; 15: 123-8.
28. Podar T, Tuomilehto J. The role of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in the management of diabetic complications. Drugs. 2002; 62: 2007-12.
29. Cameron N, Cotter M, Inkster M, Nangle M. Looking to the future: Diabetic neuropathy and effects of rosuvastatin on neurovascular function in diabetes models. Diabetes Res Clin Pract. 2003; 61: 35-9.
30. Aggarwal M, Singh J, Sood S, Arora B. Effects of lisinopril on streptozotocin-induced diabetic neuropathy in rats. Methods Find Exp Clin Pharmacol. 2001; 23: 131-4.
31. Reja A, Tesfaye S, Harris ND, Ward JD. Is ACE inhibition with lisinopril helpful in diabetic neuropathy? Diabet Med. 1995; 12: 307-9.